Skip to main content

Advertisement

Table 1 Characteristics of the studies included in the meta-analysis

From: Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects

First author Year Country Ethnicity Design Genotyping medthod Number(case/control) SNP HWE
Ruan [13] 2011 China Asian PB TaqMan 1334/1568 rs2273535 0.76
Shi [14] 2011 Sweden Caucasian PB TaqMan 763/1516 rs2273535 0.23
MARIE-GENICA [15] 2010 German Caucasian PB MALDI-TOF 3137/5469 rs2273535 0.12
rs1047972 0.17
Couch [16] 2007 CIMBA Mixed PB TaqMan 3884/3303 rs2273535 NA
Tchatchou [17] 2007 German Caucasian PB TaqMan 727/819 rs2273535 0.60
Vidarsdottir [18] 2007 Iceland Caucasian NA PCR-RFLP 759/653 rs2273535 0.07
Cox [19] 2006 USA Caucasian NA TaqMan 1259/1742 rs2273535 0.31
rs1047972 0.70
Fletcher [20] 2006 UK Caucasian PB PCR-RFLP 507/875 rs2273535 0.13
Ewart-Toland [21] 2005 USA Mixed PB SnAPSHOT 898/448 rs2273535 0.81
Lo [22] 2005 China(Taiwan) Asian HB TaqMan 709/1972 rs2273535 0.23
rs1047972 0.80
Dai [23] 2004 China Asian PB TaqMan 1102/1188 rs2273535 0.07
rs1047972 0.68
Egan [24] 2004 USA Caucasian PB Sequencing 941/830 rs2273535 0.31
rs1047972 0.68
Sun [25] 2004 China Asian HB PCR-RFLP 520/520 rs2273535 0.11
  1. HWE: Hardy-Weinberg equilibrium; PB: population based; HB: hospital-based; NA: not available; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; MALDI-TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; CIMBA: the Consortium of Investigators of Modifiers of BRCA1/2 including 16 clinic and population-based research studies and multicenter consortia.